GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (OTCPK:ONCSQ) » Definitions » Capex-to-Operating-Income

OncoSec Medical (OncoSec Medical) Capex-to-Operating-Income : 0.00 (As of Jan. 2023)


View and export this data going back to 1986. Start your Free Trial

What is OncoSec Medical Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

OncoSec Medical's Capital Expenditure for the three months ended in Jan. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Jan. 2023 was $-7.66 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


OncoSec Medical Capex-to-Operating-Income Historical Data

The historical data trend for OncoSec Medical's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Capex-to-Operating-Income Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OncoSec Medical's Capex-to-Operating-Income

For the Biotechnology subindustry, OncoSec Medical's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSec Medical's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's Capex-to-Operating-Income falls into.



OncoSec Medical Capex-to-Operating-Income Calculation

OncoSec Medical's Capex-to-Operating-Income for the fiscal year that ended in Jul. 2022 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.245) / -37.012
=N/A

OncoSec Medical's Capex-to-Operating-Income for the quarter that ended in Jan. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -7.664
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoSec Medical  (OTCPK:ONCSQ) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


OncoSec Medical Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical (OncoSec Medical) Business Description

Traded in Other Exchanges
N/A
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.
Executives
Robert J Delaversano officer: Principal Accounting Officer 217 W. MAIN STREET, SOMERVILLE NJ 08876
Spahr Stephany Foster director C/O ONCOSEC MEDICAL, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Robert H. Arch officer: President and CEO C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
George Chi officer: Chief Financial Officer 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Lin Shi director 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Margaret Dalesandro director ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Yuhang Zhao director 6 HORTON DR., CHESTER NJ 07930
Brian A Leuthner officer: Chief Operating Officer 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Daniel J. O'connor director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
China Grand Pharmaceutical & Healthcare Holdings Ltd 10 percent owner, other: See Remarks UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Alpha Holdings, Inc. director, 10 percent owner GANGNAM-GU APGUJEONG-RO 62-GIL 17-10, SEOUL M5 06016
Kellie Malloy Foerter officer: Chief Operating Officer C/O ONCOSEC MEDICAL INCORPORATED, 24 N. MAIN STREET, PENNINGTON NJ 08534-2218
Herbert Kim Lyerly director C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Chao Zhou director UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Grand Decade Developments Ltd 10 percent owner, other: See Remarks UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000